Law firm Kessler Topaz Meltzer & Check, LLP has initiated a securities fraud class action lawsuit against biopharmaceutical company uniQure N.V., alleging the firm made materially false statements regarding its investigational gene therapy candidate AMT-130 for Huntington's disease. According to the filing, uniQure allegedly misrepresented the status of FDA approval for its clinical trial design and provided inaccurate guidance on the timeline for submitting a Biologics License Application (BLA), statements that preceded a significant equity valuation event.
The alleged misstatements coincided with a substantial market reaction. On September 24, 2025, uniQure's stock price surged approximately 250% following announcements related to AMT-130. However, when the FDA reversed its position on November 3, 2025, the company's share price declined 49% in the subsequent trading period. The sharp reversal in FDA stance prompted the litigation, which targets shareholders who purchased uniQure securities during the period between September 24 and October 31, 2025.
Investors who held uniQure shares during the specified window may be eligible to participate in the class action. The deadline for joining the litigation is April 13, 2026. The case represents one of several recent securities actions arising from alleged disclosure failures in the biotechnology sector.